Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 3/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | CAMK2A | Q9UQM7 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19663936 | 0.85 | HTR2A (0.39) | MGAMGAASIMGAM2HPGD | |
| SCHEMBL10977285 | 0.77 | LMNA (0.48) | MGAMGAASIMGAM2HPGD | |
| SCHEMBL28400496 | 0.77 | HPGD (0.41) | MGAMGAASIMGAM2HPGD | |
| SCHEMBL31542585 | 0.77 | MAPT (0.58) | HPGDTSHRLMNAMAPTMAOB | |
| SCHEMBL5808039 | 0.77 | MAPT (0.58) | HPGDTSHRLMNAMAPTMAOB | |
| SCHEMBL30530217 | 0.76 | MAOB (0.50) | MGAMGAASIMGAM2GSTP1 | |
| SCHEMBL19640091 | 0.75 | KDM4E (0.44) | GAATSHRLMNAGSTP1MAPT | |
| SCHEMBL11356378 | 0.75 | MAOB (0.44) | GSTP1MAPTMAOBMEN1KMT2A | |
| SCHEMBL28398213 | 0.75 | MEN1 (0.40) | MGAMGAASIMGAM2HPGD | |
| SCHEMBL19640150 | 0.73 | HPGD (0.41) | MGAMGAASIMGAM2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111344018-B | Carfilzomib polyethylene glycol Stable compositions of compounds | 美国安进公司 | 2025-06-10 | — | — | CN | disclosed |
| US-20250177540-A1 | STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2025-06-05 | — | — | US | disclosed |
| US-20230048560-A1 | STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230048560-A1 | STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2023-02-16 | — | — | US | disclosed |
| CN-109415353-B | Pegylated carfilzomib compounds | 美国安进公司 | 2023-01-10 | — | — | CN | disclosed |
| EP-3464277-B1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-3464277-B1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-11241502-B2 | Stable compositions of pegylated carfilzomib compounds | AMGEN INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11241502-B2 | Stable compositions of pegylated carfilzomib compounds | AMGEN INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11077198-B2 | Pegylated carfilzomib compounds | AMGEN INC. (US) | 2021-08-03 | — | — | US | disclosed |
| CN-111344018-A | Stabilized compositions of pegylated carfilzomib compounds | 美国安进公司 | 2020-06-26 | — | — | CN | disclosed |
| US-10675353-B2 | Pegylated carfilzomib compounds | AMGEN INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10675353-B2 | Pegylated carfilzomib compounds | AMGEN INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200069808-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2020-03-05 | — | — | US | disclosed |
| US-20200069808-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2020-03-05 | — | — | US | disclosed |
| US-20190142957-A1 | STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2019-05-16 | — | — | US | disclosed |
| WO-2017205392-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170340746-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170340746-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170340746-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340746-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | MCL1, FCGRT, MAN2B1 | MGAM 1162/4885GAA 401/4885SI 2921/4885 |
| US-20190142957-A1 | STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS | MCL1, PHOSPHO1, PSMB5 | MGAM 625/4885GAA 288/4885SI 848/4885 |
| US-20230048560-A1 | STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS | MCL1, PHOSPHO1, PSMB5 | MGAM 625/4885GAA 288/4885SI 848/4885 |
| US-11077198-B2 | Pegylated carfilzomib compounds | FCGRT, EPOR, MCL1 | MGAM 1234/4885GAA 650/4885SI 2822/4885 |
| US-11241502-B2 | Stable compositions of pegylated carfilzomib compounds | MCL1, PHOSPHO1, PSMB5 | MGAM 625/4885GAA 288/4885SI 848/4885 |
| US-20250177540-A1 | STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS | MCL1, PHOSPHO1, PSMB5 | MGAM 625/4885GAA 288/4885SI 848/4885 |
| US-10675353-B2 | Pegylated carfilzomib compounds | FCGRT, EPOR, MCL1 | MGAM 1234/4885GAA 650/4885SI 2822/4885 |
| US-20200069808-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | FCGRT, EPOR, MCL1 | MGAM 1234/4885GAA 650/4885SI 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.